RECBIO has obtained approval for the CHO cell vaccine expansion

AASTOCKS
2025.11.16 10:42

RECBIO-B (02179.HK) announced that it recently received additional approval from the Jiangsu Provincial Drug Administration, expanding the production scope to include recombinant shingles vaccine (CHO cells) and related adjuvant components. This marks a further expansion of the group's research and production capabilities in the field of preventive biological products

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer